- One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts.
- Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline.
- The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented technology that protects and potentiates the virotherapy during administration (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) to target and destroy cancer cells while simultaneously stimulating the immune system. The company’s groundbreaking work has positioned it as a leader in the development of next-generation cancer treatments.
In recent news, Calidi has made two major announcements that underscore its progress, one related to its strengthened financial position and another highlighting its acceptance into a prestigious scientific seminar to present new research. These developments signal the company’s growth and its continued advancement toward commercializing its therapies.
One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi Biotherapeutics recently announced that it has strengthened its financial position, ensuring continued progress in its clinical and preclinical programs (https://ibn.fm/9JicX). As of Dec. 31, 2024, Calidi reported a cash balance of approximately $9.6 million. This increase is largely due to successful fundraising efforts, including proceeds from the company’s At-the-Market Offering Agreement (“ATM”).
As a result of these efforts, Calidi was able to terminate its Standby Equity Purchase Agreement (“SEPA”) with YA II PN Ltd., an affiliate of Yorkville Advisors, effective Jan. 23, 2025. The infusion of capital will allow the company to further refine its oncolytic virotherapy platforms, expand its clinical trials, and enhance its overall operational stability.
Additionally, Calidi announced the successful closing of a public offering on Jan. 10, 2025, which raised an additional $4.25 million in gross proceeds. This contributes to the ongoing development of Calidi’s proprietary technologies and supports the company’s mission to bring effective cancer therapies to market. This improved financial footing not only reassures investors but also allows Calidi to focus on achieving key milestones in its research pipeline. With adequate funding in place, the company is well-positioned to continue its groundbreaking work in cancer immunotherapy.
Beyond its financial achievements, Calidi Biotherapeutics has also made headlines for its acceptance into a major scientific conference where it will present its latest research findings (https://ibn.fm/WZ1RO). The company announced that it has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious American Association for Cancer Research (“AACR”) annual meeting in April 2025.
This recognition marks an important milestone for Calidi, as the AACR annual meeting is one of the most influential conferences in the field of cancer research. Being accepted to present at this event underscores the significance of Calidi’s work and its potential to revolutionize cancer treatment.
Calidi’s RTNova platform is designed to overcome the limitations of traditional virotherapy by enabling systemic delivery and enhancing the targeting of metastatic tumors. Antitumor virotherapies have long been recognized for their ability to selectively infect and kill cancer cells, but challenges such as immune system clearance and limited distribution have hindered their full potential. The RTNova platform addresses these challenges by utilizing an extracellular enveloped virus (“EEV”) as a delivery mechanism, allowing the therapeutic viruses to reach tumors more effectively while evading premature destruction by the immune system. These preclinical findings highlight the RTNova platform’s ability to effectively target and treat metastatic cancer cells and represent a significant advancement in the field of cancer virotherapy.
In addition to the RTNova platform, Calidi is actively developing other innovative therapies aimed at harnessing the immune system to combat cancer. The company’s approach to immunotherapy focuses on protecting the viral payload to enhance the efficacy of antitumor viruses, potentially improving outcomes for patients with hard-to-treat cancers.
With a strengthened financial position and the recognition of its research by a leading scientific organization, Calidi Biotherapeutics is poised for continued growth. The company’s ability to secure funding ensures that it can maintain momentum in its clinical and preclinical programs, while its acceptance into a high-profile scientific seminar validates the importance of its work. As Calidi moves forward, it is well-positioned to make a lasting impact in the biotechnology industry. With continued innovation and a strong financial foundation, the company is set to play a crucial role in the future of cancer immunotherapy.
For more information, visit www.CalidiBio.com.
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
